Tirzepatide and bullous pemphigoid

A case report published in August 2026 in the Journal of the German Society of Dermatology describes a patient who developed bullous pemphigoid while taking tirzepatide, the dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound^[1]. Bullous pemphigoid had not previously appeared in tirzepatide's prescribing information. The case is the first published report linking tirzepatide specifically to this autoimmune blistering condition, and it raises questions that sit alongside a broader, still-unresolved story about diabetes drugs and skin immunity.

What is bullous pemphigoid

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, accounting for roughly 80% of subepidermal immunobullous cases^[2]. The body produces autoantibodies against two structural proteins in the skin, BP180 and BP230, which anchor the outer skin layer to the dermis. When these proteins are attacked, fluid-filled blisters form along the skin's junction layers, typically on the trunk and limbs.

The condition primarily affects people aged 60 to 80, with incidence estimated at 6 to 13 new cases per million annually in the US and 12 to 13 per million in Central Europe. It can be life-threatening in older or immunocompromised patients and usually requires systemic treatment.

Drug-induced bullous pemphigoid: an established phenomenon

Certain medicines have long been implicated in triggering BP. Drug-induced cases typically emerge within three months of starting a new medication^[2]. The drug classes most consistently linked include diuretics, NSAIDs, antibiotics, checkpoint inhibitors (PD-1 and PD-L1 blockers), and, most relevant to this case, antidiabetic agents.

The clearest established link is with DPP-4 inhibitors (the gliptin class: sitagliptin, vildagliptin, saxagliptin). Multiple pharmacovigilance studies and case series have found an elevated BP risk with these drugs compared to other antidiabetic agents. The mechanism proposed is that DPP-4 inhibition may alter immune regulation in the skin, though the precise pathway remains contested.

Tirzepatide acts on a different mechanism than DPP-4 inhibitors: it is a dual GIP/GLP-1 receptor agonist, not an enzyme inhibitor^[3]. Whether the tirzepatide case represents a class effect shared with GLP-1 receptor agonists, a unique property of the dual-agonist mechanism, or a coincidence in a single patient is not answerable from one case report.

What the case report describes

The Spanish authors, Hernandez Madrid and colleagues, describe a patient who developed bullous pemphigoid after starting tirzepatide^[1]. The report is published online ahead of print in the JDDG (Journal of the German Society of Dermatology), a peer-reviewed journal indexed by PubMed. Full clinical details of the case, including the patient's age, comorbidities, time to onset, and immunofluorescence findings, are in the paper itself, which was not yet freely accessible at the time of writing.

The title frames tirzepatide as a "possible trigger," not a confirmed cause. That framing reflects the standard epistemic caution in single-case dermatology reports: association in one patient does not establish causation. It does, however, establish plausibility and flags a signal worth watching.

Where the GLP-1 and skin question stands more broadly

A 2024 review in Archives of Dermatological Research catalogued rare cutaneous adverse reactions reported across the GLP-1 receptor agonist class^[4]. The review found that bullous pemphigoid had appeared in published literature linked to GLP-1 medications, though the total case count at that time remained low. The authors concluded that rare but significant cutaneous adverse reactions had been documented, and called for clinician awareness.

The current tirzepatide prescribing information, per the DailyMed label, lists urticaria, eczema, and alopecia as dermatological reactions in clinical or post-marketing experience, but does not list bullous pemphigoid. If additional cases accumulate, that could change through a label update or a post-marketing safety communication.

What we do not yet know

Several questions remain open. The mechanism by which a GIP/GLP-1 dual agonist might trigger autoantibody formation against BP180 or BP230 has not been established. There is no pharmacovigilance dataset yet examining BP incidence rates in tirzepatide users compared to matched controls. Whether the tirzepatide case resolves after stopping the drug (as some drug-induced BP cases do) is not reported in the available abstract information.

The clinical question for prescribers and patients is straightforward: if new blistering skin lesions develop in someone on tirzepatide, bullous pemphigoid is now on the differential, and dermatology referral is appropriate. This is not a reason to avoid tirzepatide, whose benefits across the SURMOUNT and SURPASS trial programmes are well-documented, but it is a reason to investigate unexplained blistering without delay.

What to watch

This case report is the first; whether it becomes part of a pattern depends on what accumulates in pharmacovigilance databases and case series over the coming months. For background on the tirzepatide trial programme and the broader clinical picture, see the tirzepatide peptide page on this site. For country-specific regulatory status, including current label updates, see the relevant tirzepatide regulation pages. If the FDA or EMA issues a safety communication about this signal, we will update this article.